ArticleClinical drug investigation2023

Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.

Shijie Lu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.